Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 in patients with PSA progression without clinical progression
2014-002833-70Phase 3Completed
- Sponsor
- UZ Leuven
- Start
- Dec 2014
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of radium-223 dichloride in prostate cancer (PCa), sponsored by UZ Leuven. Primary endpoint: Safety and tolerability of radium-223. Started Dec 2014; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2014-002833-70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002833-70.